Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update Life Science Investing
Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader Life Science Investing
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference Life Science Investing
Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference Life Science Investing
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference Life Science Investing
Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS Life Science Investing
Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference Life Science Investing
